Literature DB >> 14871428

FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury.

Duska Dragun1, Torsten Böhler, Melina Nieminen-Kelhä, Johannes Waiser, Wolfgang Schneider, Hermann Haller, Friedrich C Luft, Klemens Budde, Hans-Hellmut Neumayer.   

Abstract

BACKGROUND: A novel immunomodulator, FTY720, modulates lymphocyte migration to injured tissues via enhanced lymphocyte sequestration to secondary lymphoid organs. We tested whether or not single-dose FTY720 (0.5 mg/kg) pretreatment rescues renal grafts from post-transplant preservation/reperfusion injury.
METHODS: Rat renal grafts were cold-preserved in University of Wisconsin (UW) solution for 4 hours and then transplanted into syngeneic or allogeneic recipients that received a single dose of FTY720 24 hours before transplantation. Flow cytometry analysis of peripheral blood and lymph nodes was performed to confirm the biologic effect of FTY720. Grafts were harvested after 24 hours. Renal sections were examined histologically and stained for intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1), platelet endothelial cellular adhesion molecule-1 (PECAM-1), major histocompatibility complex (MHC) class II, and inflammatory cells. Interleukin-1 (IL-1) production was determined in renal protein extracts.
RESULTS: FTY720 pretreatment significantly increased CD3+ T-cell sequestration to lymph nodes in the face of peripheral lymphopenia. Isografts and allografts from the FTY720-treated groups did not develop increased creatinine (0.55 +/- 0.12 in isografts and 0.62 +/- 0.08 mg/dL in allografts), compared with vehicle controls (2.28 +/- 0.20 in isografts and 2.24 +/- 0.18 mg/dL in allografts). Kidneys from FTY720-treated groups also showed lower acute tubular damage scores. Furthermore, FTY720 decreased neutrophil influx, although circulating neutrophils were unchanged. FTY720 also prevented postischemic IL-1 intragraft production not affecting infiltration with recipient ED-1+ macrophages and MHC class II-positive cells. Expression of ICAM-1, VCAM-1, and PECAM did not differ among groups.
CONCLUSION: FTY720 ameliorated morphologic and functional consequences of post-transplant reperfusion injury. Thus, FTY720-induced peripheral T-cell absence may influence intragraft IL-1 production and neutrophil infiltration, despite proadhesive endothelial properties. FTY720 may broaden the utility in renal transplantation as a pretreatment strategy against preservation/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871428     DOI: 10.1111/j.1523-1755.2004.00478.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Immunotherapy for De Novo renal transplantation: what's in the pipeline?

Authors:  Helio Tedesco Silva; Paula Pinheiro Machado; Claudia Rosso Felipe; Jose Osmar Medina Pestana
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Ischemia-reperfusion and immediate T cell responses.

Authors:  Yanfei Huang; Hamid Rabb; Karl L Womer
Journal:  Cell Immunol       Date:  2007-10-17       Impact factor: 4.868

Review 3.  The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.

Authors:  Michael D Davis; John H Kehrl
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

4.  Protective effects of early CD4(+) T cell reduction in hepatic ischemia/reperfusion injury.

Authors:  Mathias Martin; Christina Mory; Andrea Prescher; Christian Wittekind; Martin Fiedler; Dirk Uhlmann
Journal:  J Gastrointest Surg       Date:  2009-11-25       Impact factor: 3.452

Review 5.  Lymphocytes and ischemia-reperfusion injury.

Authors:  Douglas Linfert; Tayseer Chowdhry; Hamid Rabb
Journal:  Transplant Rev (Orlando)       Date:  2009-01       Impact factor: 3.943

6.  Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.

Authors:  Hany A Omar; Chih-Chien Chou; Lisa D Berman-Booty; Yihui Ma; Jui-Hsiang Hung; Dasheng Wang; Takayuki Kogure; Tushar Patel; Luigi Terracciano; Natarajan Muthusamy; John C Byrd; Samuel K Kulp; Ching-Shih Chen
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.298

7.  Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants.

Authors:  Reza Soleimani; Elke Heytens; Kutluk Oktay
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine.

Authors:  Jason S Hawksworth; J Christopher Graybill; Trevor S Brown; Shannon M Wallace; Thomas A Davis; Doug K Tadaki; Eric A Elster
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

9.  Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis.

Authors:  Damian J Mole; Scott P Webster; Iain Uings; Xiaozhong Zheng; Margaret Binnie; Kris Wilson; Jonathan P Hutchinson; Olivier Mirguet; Ann Walker; Benjamin Beaufils; Nicolas Ancellin; Lionel Trottet; Véronique Bénéton; Christopher G Mowat; Martin Wilkinson; Paul Rowland; Carl Haslam; Andrew McBride; Natalie Z M Homer; James E Baily; Matthew G F Sharp; O James Garden; Jeremy Hughes; Sarah E M Howie; Duncan S Holmes; John Liddle; John P Iredale
Journal:  Nat Med       Date:  2016-01-11       Impact factor: 53.440

10.  Administration of FTY720 during Tourniquet-Induced Limb Ischemia Reperfusion Injury Attenuates Systemic Inflammation.

Authors:  Anthony D Foster; Diego Vicente; Jonathan J Sexton; Luke Johnston; Nick Clark; Crystal Leonhardt; Eric A Elster; Thomas A Davis; Matthew J Bradley
Journal:  Mediators Inflamm       Date:  2017-12-19       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.